Skip to content

Clinical study of shengefang combined with daily diet and exercise in the treatment of metabolic related fatty liver disease

Clinical study of shengefang combined with daily diet and exercise in the treatment of metabolic related fatty liver disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040993
Enrollment
Unknown
Registered
2020-12-16
Start date
2020-12-15
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic fatty liver disease

Interventions

Sponsors

Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The diagnostic criteria of mafld were met; 2. According to the TCM syndrome differentiation standard of spleen deficiency and phlegm dampness with blood stasis syndrome; 3. The age ranged from 18 to 65 years old; 4. They voluntarily accepted the treatment of shengefang and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with acute fatty liver of pregnancy, Reye syndrome (acute encephalopathy complicated with visceral steatosis syndrome), lipoid deposition disease, focal fatty liver, hepatic fatty tumor, etc. 2. Viral hepatitis, drug-induced liver disease, total parenteral nutrition, hepatolenticular degeneration, autoimmune liver disease and other specific diseases can lead to fatty liver. 3. Alt, AST >= 5 x ULN, or TBIL >= 5 x ULN. 4. He took liver protecting drugs, lipid-lowering and weight-loss drugs within 2 weeks before entering the group. 5. Patients with heart, brain, kidney (BUN > 1.5 times of the upper limit of normal value, SCR > upper limit of normal value), hematopoietic system and other serious primary diseases, psychosis and clinically significant abnormal ECG. 6. A woman who is pregnant or ready to conceive, a lactating woman. 7. Those who are known to be allergic to ingredients of shengefang or allergic constitution. 8. Patients suspected of having a history of drug abuse or indeed reducing the possibility of enrollment. 9. Cognitive dysfunction can not give full informed consent. 10. Patients who participated in other clinical trials in the past month.

Design outcomes

Primary

MeasureTime frame
Measurement of proton density and fat content in magnetic resonance imaging;

Secondary

MeasureTime frame
liver function;blood fat;FibroScan;BMI;TCM clinical symptom score;

Countries

China

Contacts

Public ContactLyu Jia

Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine

lvjia1030@163.com+86 15921178295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026